Practice pattern and use of a novel skin moisturizer containing skin barrier therapy in patients with atopic dermatitis: a cross-sectional survey among dermatologists in India


  • Anil Abraham Abrahams Skin & Hair Clinic, Bengaluru, Karnataka, India
  • Anil Ganjoo Dr. Ganjoo’s Skin and Cosmetology Centre, New Delhi, India
  • Sheilly Kapoor Rejuva Skin Clinic, Gurugram, Haryana, India
  • Divya Sharma Dr. Divya’s Skin and Hair Solution, Bengaluru, Karnataka, India
  • Abhay Talathi SkinSpace Clinic, Mumbai, Maharashtra, India



Atopic dermatitis, Survey, Skin moisturizer, Skin barrier therapy


Background: Atopic dermatitis is considered as the most common chronic, inflammatory dermatological disorder. Skin barrier dysfunction represents an early pathology of this condition. Various factors contribute to development of such defects. Skin moisturizers remain the mainstay of therapy for AD along with other treatment modalities.

Methods: Dermatologists across India were administered a questionnaire consisting of questions related to number of the patients seen with AD every week and their clinical experience regarding the use of novel skin moisturizer containing skin barrier therapy for the management of AD. The responses were analysed as number and percentages.

Results: A total of 1605 patients were included in this survey. The complete responses were obtained from a total of 58 dermatologists. The majority (98%) of the dermatologists found the overall efficacy of novel skin moisturizer (Atoderm Intensive Baume) in AD patients as ‘satisfactory’. Atoderm Intensive Baume was found as efficacious in improving various parameters of AD such as skin dryness, severity of pruritus, inflammation, insomnia, itching, and urge to scratch. It was also well tolerated. It plays an important role in the repair of damaged skin barrier caused by AD.

Conclusions: This survey findings indicated that novel skin moisturizer (Atoderm Intensive Baume) is a preferred formulation by dermatologists across India for the management of AD with proven efficacy and safety.


Bieber T. Atopic dermatitis. Ann Dermatol. 2010;22(2):125-37.

Cork MJ, Danby SG, Ogg GS. Atopic dermatitis epidemiology and unmet need in the United Kingdom. J Dermatolog Treat. 2020;31(8):801-9.

Kim BE, Leung DYM. Significance of Skin Barrier Dysfunction in Atopic Dermatitis. Allergy Asthma Immunol Res. 2018;10(3):207-15.

Kenna SP, Doward LC. Quality of life of children with atopic dermatitis and their families. Curr Opin Allergy Clin Immunol. 2008;8(3):228-31.

Valdman-Grinshpoun Y, Ben-Amitai D, Zvulunov A. Barrier-restoring therapies in atopic dermatitis: current approaches and future perspectives. Dermatol Res Pract. 2012;923134.

Wollenberg A, Christen ZS, Taieb A, Paul C, Thyssen JP, Weller M, et al. ETFAD/EADV Eczema task force 2020 position paper on diagnosis and treatment of atopic dermatitis in adults and children. J Eur Acad Dermatol Venereol. 2020;34(12):2717-44.

Murota H, Inoue S, Yoshida K, Ishimoto A. Cost of illness study for adult atopic dermatitis in Japan: A cross-sectional Web-based survey. J Dermatol. 2020;47(7):689-98.

Gayraud F, Sayag M, Jourdan E. Efficacy and tolerance assessment of a new type of dermocosmetic in infants and children with moderate atopic dermatitis. J Cosmet Dermatol. 2015;14(2):107-12.

Gold MH. The Importance of Skin Barrier Function in Atopic Dermatitis Patients, 2018. Available at: Accessed on 4 July 2021.






Original Research Articles